Product Description
Weill Medical College of Cornell University is developing 225AC-J591 as a treatment for prostate cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03276572)
Mechanisms of Action: PSMA Binder
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Weill Medical College of Cornell University
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Prostate Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04946370 |
NCT04946370 | P2 |
Recruiting |
Prostate Cancer |
2027-10-01 |
12% |
2026-04-23 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |